BioSpecifics Technologies Corp. (NASDAQ:BSTC) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price objective of $65.00 for the company and are forecasting that the company will post $0.39 EPS for the current quarter, according to Zacks. Zacks has also given BioSpecifics Technologies an industry rank of 181 out of 265 based on the ratings given to related companies.
Several equities analysts have recently weighed in on BSTC shares. Zacks Investment Research downgraded BioSpecifics Technologies from a “buy” rating to a “hold” rating in a report on Friday, January 12th. HC Wainwright restated a “buy” rating on shares of BioSpecifics Technologies in a report on Tuesday, December 26th. Finally, reduced their price target on BioSpecifics Technologies from $72.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 15th.
Large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its holdings in shares of BioSpecifics Technologies by 1.5% during the third quarter. Dimensional Fund Advisors LP now owns 269,554 shares of the biopharmaceutical company’s stock valued at $12,540,000 after acquiring an additional 3,878 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of BioSpecifics Technologies by 94.3% during the second quarter. Goldman Sachs Group Inc. now owns 112,894 shares of the biopharmaceutical company’s stock valued at $5,589,000 after buying an additional 54,777 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of BioSpecifics Technologies by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,454 shares of the biopharmaceutical company’s stock valued at $9,924,000 after buying an additional 3,030 shares during the last quarter. First Quadrant L P CA boosted its position in shares of BioSpecifics Technologies by 52.7% during the fourth quarter. First Quadrant L P CA now owns 11,631 shares of the biopharmaceutical company’s stock valued at $504,000 after buying an additional 4,015 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of BioSpecifics Technologies by 5.4% during the second quarter. Northern Trust Corp now owns 84,533 shares of the biopharmaceutical company’s stock valued at $4,185,000 after buying an additional 4,351 shares during the last quarter. Hedge funds and other institutional investors own 55.66% of the company’s stock.
BioSpecifics Technologies (NASDAQ:BSTC) traded down $0.92 on Friday, reaching $39.03. The company’s stock had a trading volume of 23,300 shares, compared to its average volume of 28,148. The company has a market capitalization of $287.21, a P/E ratio of 24.55 and a beta of 1.55. BioSpecifics Technologies has a twelve month low of $38.05 and a twelve month high of $58.79.
TRADEMARK VIOLATION WARNING: “Zacks: BioSpecifics Technologies Corp. (BSTC) Given Average Recommendation of “Strong Buy” by Brokerages” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/21/zacks-biospecifics-technologies-corp-bstc-given-average-recommendation-of-strong-buy-by-brokerages.html.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Get a free copy of the Zacks research report on BioSpecifics Technologies (BSTC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.